Success and Limitation of Equine Influenza Vaccination: The First Incursion in a Decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage.

DIVA test Florida Clade 1 (FC1) epizooty equine influenza virus horse immune coverage surveillance vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
02 Nov 2019
Historique:
received: 05 10 2019
revised: 28 10 2019
accepted: 31 10 2019
entrez: 6 11 2019
pubmed: 7 11 2019
medline: 7 11 2019
Statut: epublish

Résumé

Every year, several epizooties of equine influenza (EI) are reported worldwide. However, no EI case has been identified in France between 2015 and late 2018, despite an effective field surveillance of the pathogen and the disease. Vaccination against equine influenza virus (EIV) remains to this day one of the most effective methods to prevent or limit EI outbreaks and the lack of detection of the pathogen could be linked to vaccination coverage. The aim of this study was to evaluate EI immunity and vaccine coverage in France through a large-scale serological study. A total of 3004 archived surplus serums from French horses of all ages, breeds and sexes were selected from four different geographical regions and categories (i.e., sanitary check prior to exportation, sale, breeding protocol or illness diagnosis). EIV-specific antibody response was measured by single radial hemolysis (SRH) and an EIV-nucleoprotein (NP) ELISA (used as a DIVA test). Overall immunity coverage against EIV infection (i.e., titers induced by vaccination and/or natural infection above the clinical protection threshold) reached 87.6%. The EIV NP ELISA results showed that 83% of SRH positive serum samples from young horses (≤3 years old) did not have NP antibodies, which indicates that the SRH antibody response was likely induced by EI vaccination alone (the HA recombinant canarypoxvirus-based EI vaccine is mostly used in France) and supports the absence of EIV circulation in French horse populations between 2015 and late 2018, as reported by the French equine infectious diseases surveillance network (RESPE). Results from this study confirm a strong EI immunity in a large cohort of French horses, which provides an explanation to the lack of clinical EI in France in recent years and highlights the success of vaccination against this disease. However, such EI protection has been challenged since late 2018 by the incursion in the EU of a Florida Clade 1 sub-lineage EIV (undetected in France since 2009), which is also reported here.

Identifiants

pubmed: 31684097
pii: vaccines7040174
doi: 10.3390/vaccines7040174
pmc: PMC6963532
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : IFCE
ID : 2017-008
Organisme : Fonds Eperon
ID : N12-2017
Organisme : Région Normandie
ID : 17E01598/17P04324

Déclaration de conflit d'intérêts

Authors report no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Références

Equine Vet J. 2011 Sep;43(5):608-17
pubmed: 21496094
Vaccine. 2011 Nov 15;29(49):9214-23
pubmed: 21983355
Vaccines (Basel). 2014 Nov 14;2(4):797-831
pubmed: 26344892
Influenza Other Respir Viruses. 2013 Dec;7 Suppl 4:73-80
pubmed: 24224822
Vet Rec. 2019 Jan 19;184(3):101
pubmed: 30655407
MMWR Morb Mortal Wkly Rep. 2017 Sep 29;66(38):1028
pubmed: 28957041
Front Microbiol. 2018 Sep 06;9:1941
pubmed: 30237788
Dev Biol Stand. 1992;79:137-46
pubmed: 1286748
Pathogens. 2017 Feb 08;6(1):
pubmed: 28208721
Influenza Other Respir Viruses. 2013 Dec;7 Suppl 4:61-72
pubmed: 24224821
BMC Infect Dis. 2018 Mar 13;18(1):128
pubmed: 29534676
Vaccine. 2009 Sep 4;27(40):5530-7
pubmed: 19607950
Pathogens. 2016 Nov 25;5(4):
pubmed: 27897990
Vaccine. 2016 Jul 19;34(33):3787-95
pubmed: 27269055
Virol J. 2014 Sep 02;11:159
pubmed: 25183201
Vet Microbiol. 2014 Mar 14;169(3-4):113-27
pubmed: 24480583
Vaccine. 2011 May 17;29(22):3917-22
pubmed: 21419776
Vaccine. 1994 Jul;12(9):857-63
pubmed: 7975864
Vaccine. 2010 Oct 8;28(43):6989-96
pubmed: 20728523
Braz J Microbiol. 2018 Apr - Jun;49(2):336-346
pubmed: 29100932
Vaccine. 2018 Jun 14;36(25):3666-3673
pubmed: 29739721
Pharmeuropa Bio. 2007 Dec;2007(1):7-14
pubmed: 18413133
Virology. 2017 May;505:210-217
pubmed: 28292661
Influenza Other Respir Viruses. 2016 Jan;10(1):37-46
pubmed: 26406274
Pathogens. 2016 Jun 10;5(2):null
pubmed: 27294963
Vet J. 2007 Nov;174(3):592-8
pubmed: 17560150
Res Vet Sci. 2013 Oct;95(2):418-24
pubmed: 23768693
Vaccines (Basel). 2018 Jul 02;6(3):null
pubmed: 30004410
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Vet Microbiol. 2017 Nov;211:150-159
pubmed: 29102112
Transbound Emerg Dis. 2018 Dec;65(6):1408-1415
pubmed: 30054993
Vaccine. 2017 Sep 18;35(39):5291-5296
pubmed: 28666760
Int J Infect Dis. 2017 Dec;65:122-127
pubmed: 29042178

Auteurs

Stéphanie Fougerolle (S)

Frank Duncombe, LABÉO, 14280 Saint Contest, France. st.fougerolle@gmail.com.
NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. st.fougerolle@gmail.com.

Christine Fortier (C)

Frank Duncombe, LABÉO, 14280 Saint Contest, France. christine.fortier@laboratoire-labeo.fr.
NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. christine.fortier@laboratoire-labeo.fr.

Loïc Legrand (L)

Frank Duncombe, LABÉO, 14280 Saint Contest, France. loic.legrand@laboratoire-labeo.fr.
NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. loic.legrand@laboratoire-labeo.fr.
RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. loic.legrand@laboratoire-labeo.fr.

Marion Jourdan (M)

RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. technicien@respe.net.

Christel Marcillaud-Pitel (C)

RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. c.marcillaud-pitel@respe.net.

Stéphane Pronost (S)

Frank Duncombe, LABÉO, 14280 Saint Contest, France. stephane.pronost@laboratoire-labeo.fr.
NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. stephane.pronost@laboratoire-labeo.fr.
RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. stephane.pronost@laboratoire-labeo.fr.

Romain Paillot (R)

Frank Duncombe, LABÉO, 14280 Saint Contest, France. romain.paillot@laboratoire-labeo.fr.
NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. romain.paillot@laboratoire-labeo.fr.
RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. romain.paillot@laboratoire-labeo.fr.

Classifications MeSH